Incyte Corp. (INCY)
112.73
-0.06
(-0.05%)
USD |
NASDAQ |
Oct 12, 12:22
Incyte Free Cash Flow (Quarterly) : 495.25M for June 30, 2026
Free Cash Flow (Quarterly) Chart
Historical Free Cash Flow (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 495.25M |
| March 31, 2026 | 354.15M |
| December 31, 2025 | 521.42M |
| September 30, 2025 | 519.64M |
| June 30, 2025 | 25.67M |
| March 31, 2025 | 262.90M |
| December 31, 2024 | 363.83M |
| September 30, 2024 | 293.18M |
| June 30, 2024 | -631.11M |
| March 31, 2024 | 209.26M |
| December 31, 2023 | 145.46M |
| September 30, 2023 | 136.86M |
| June 30, 2023 | 299.19M |
| March 31, 2023 | -132.51M |
| December 31, 2022 | 262.39M |
| September 30, 2022 | 268.57M |
| June 30, 2022 | 162.41M |
| March 31, 2022 | 198.74M |
| December 31, 2021 | 80.89M |
| September 30, 2021 | 222.94M |
| June 30, 2021 | 106.64M |
| March 31, 2021 | 158.01M |
| December 31, 2020 | 55.89M |
| September 30, 2020 | 129.29M |
| June 30, 2020 | 225.52M |
| Date | Value |
|---|---|
| March 31, 2020 | -722.68M |
| December 31, 2019 | 102.30M |
| September 30, 2019 | 287.23M |
| June 30, 2019 | 105.67M |
| March 31, 2019 | 137.40M |
| December 31, 2018 | 58.56M |
| September 30, 2018 | 174.33M |
| June 30, 2018 | 21.61M |
| March 31, 2018 | 8.248M |
| December 31, 2017 | -105.58M |
| September 30, 2017 | 18.82M |
| June 30, 2017 | 85.46M |
| March 31, 2017 | -202.70M |
| December 31, 2016 | 78.51M |
| September 30, 2016 | 78.64M |
| June 30, 2016 | -64.64M |
| March 31, 2016 | 91.97M |
| December 31, 2015 | 63.11M |
| September 30, 2015 | -5.635M |
| June 30, 2015 | 11.19M |
| March 31, 2015 | -8.139M |
| December 31, 2014 | 39.24M |
| September 30, 2014 | 16.75M |
| June 30, 2014 | -23.26M |
| March 31, 2014 | -34.62M |
Free Cash Flow Definition
Free Cash Flow is the cash a company has left after paying for its day-to-day operations and investing in its physical assets, such as buildings, equipment and technology. The company can use that cash however it chooses: paying dividends, buying back shares, paying down debt, making acquisitions or keeping it for future growth.
Free Cash Flow (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Free Cash Flow (Quarterly) Benchmarks
| Regeneron Pharmaceuticals, Inc. | 521.80M |
| Mirum Pharmaceuticals, Inc. | -69.28M |
| Alnylam Pharmaceuticals, Inc. | 292.04M |
| Vertex Pharmaceuticals, Inc. | 1.013B |
| AbbVie, Inc. | 3.114B |